Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene therapy designed to restore a neurosensory function to normal levels. The post Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.